fluvoxamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1230	54739-18-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: fluvoxamine fluvoxamine maleate depromel	A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS. Because of its high affinity at the sigma-1 receptor, the drug was evaluated whether could prevent clinical deterioration in patients with COVID-19. At the moment, there are insufficient data to recommend either for or against use of fluvoxamine for the treatment of COVID-19. Molecular weight: 318.34 Formula: C15H21F3N2O2 CLOGP: 2.77 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 56.84 ALOGS: -4.64 ROTB: 10 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

fluvoxamine
fluvoxamine maleate
depromel

A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS. Because of its high affinity at the sigma-1 receptor, the drug was evaluated whether could prevent clinical deterioration in patients with COVID-19. At the moment, there are insufficient data to recommend either for or against use of fluvoxamine for the treatment of COVID-19.

Molecular weight: 318.34
Formula: C15H21F3N2O2
CLOGP: 2.77
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 56.84
ALOGS: -4.64
ROTB: 10

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	14.87 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	2 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	13.46 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	53 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	23.50 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	31.95 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.20 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	12.50 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 5, 1994	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug interaction	270.34	19.17	204	5856	209551	56076456
Myoglobin urine present	200.30	19.17	37	6023	529	56285478
Serotonin syndrome	170.23	19.17	74	5986	26416	56259591
Suicide attempt	133.51	19.17	81	5979	57755	56228252
Intentional self-injury	126.14	19.17	59	6001	24933	56261074
Toxic encephalopathy	117.99	19.17	38	6022	5900	56280107
Amylase increased	114.95	19.17	37	6023	5734	56280273
Intentional overdose	111.80	19.17	77	5983	68040	56217967
Blood creatine phosphokinase increased	110.97	19.17	56	6004	27896	56258111
Troponin increased	104.05	19.17	38	6022	8597	56277410
Blood potassium increased	81.69	19.17	39	6021	17222	56268785
Blood lactate dehydrogenase increased	80.80	19.17	41	6019	20634	56265373
Toxicity to various agents	79.93	19.17	109	5951	224455	56061552
Drug abuse	74.08	19.17	60	6000	67550	56218457
Neuroleptic malignant syndrome	70.20	19.17	31	6029	11447	56274560
Somnolence	60.61	19.17	81	5979	163332	56122675
Mydriasis	49.30	19.17	24	6036	11047	56274960
Suicidal ideation	48.44	19.17	44	6016	57698	56228309
Alanine aminotransferase increased	46.86	19.17	54	6006	93608	56192399
Oscillopsia	42.27	19.17	8	6052	131	56285876
Electrocardiogram QT prolonged	40.78	19.17	39	6021	54549	56231458
Galactorrhoea	39.10	19.17	15	6045	3880	56282127
Anxiety	38.43	19.17	72	5988	193100	56092907
Drug level increased	37.68	19.17	25	6035	20700	56265307
Obsessive-compulsive disorder	36.23	19.17	14	6046	3692	56282315
Schizophrenia	35.78	19.17	19	6041	10480	56275527
Overdose	32.54	19.17	48	6012	105782	56180225
Completed suicide	31.88	19.17	54	6006	133779	56152228
Depression	27.30	19.17	60	6000	180057	56105950
Tremor	26.41	19.17	47	6013	121042	56164965
Obsessive-compulsive symptom	26.19	19.17	5	6055	86	56285921
Restlessness	25.76	19.17	22	6038	26564	56259443
Torsade de pointes	25.05	19.17	16	6044	12424	56273583
Agitation	24.20	19.17	30	6030	56006	56230001
Alice in wonderland syndrome	23.88	19.17	4	6056	31	56285976
Sopor	23.79	19.17	19	6041	20903	56265104
Rheumatoid arthritis	23.73	19.17	6	6054	382598	55903409
Drug screen false positive	23.71	19.17	7	6053	813	56285194
Akinesia	23.20	19.17	8	6052	1528	56284479
Anaemia folate deficiency	22.39	19.17	5	6055	190	56285817
Personality disorder	22.38	19.17	11	6049	5162	56280845
Mental disorder	21.79	19.17	19	6041	23585	56262422
Congestive cardiomyopathy	21.16	19.17	11	6049	5808	56280199
Extrapyramidal disorder	20.30	19.17	14	6046	12342	56273665
Miosis	19.87	19.17	11	6049	6581	56279426
Psychotic disorder	19.83	19.17	18	6042	23540	56262467
Aspiration of gastric residual	19.58	19.17	3	6057	12	56285995

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Loss of libido	198.84	25.17	52	5549	2343	31689400
Apathy	147.78	25.17	52	5549	6430	31685313
Drug interaction	147.44	25.17	182	5419	208361	31483382
Schizophrenia	142.06	25.17	58	5543	10772	31680971
Psychotic disorder	127.15	25.17	67	5534	22226	31669517
Suicidal ideation	118.53	25.17	76	5525	36330	31655413
Sedation	116.74	25.17	60	5541	18905	31672838
Serotonin syndrome	97.41	25.17	53	5548	18720	31673023
Persecutory delusion	77.89	25.17	25	5576	2327	31689416
Neuroleptic malignant syndrome	74.89	25.17	43	5558	16826	31674917
Encephalitis toxic	70.36	25.17	15	5586	273	31691470
Drug level increased	67.76	25.17	43	5558	20143	31671600
Salivary hypersecretion	67.00	25.17	31	5570	7761	31683982
Obsessive-compulsive disorder	66.61	25.17	27	5574	4910	31686833
Social avoidant behaviour	64.19	25.17	23	5578	2990	31688753
Catatonia	63.82	25.17	26	5575	4788	31686955
Suicide attempt	62.25	25.17	52	5549	37196	31654547
Weight increased	59.17	25.17	73	5528	82874	31608869
Depression	57.01	25.17	75	5526	90740	31601003
Overdose	56.38	25.17	72	5529	84592	31607151
Orthostatic hypotension	53.94	25.17	40	5561	24079	31667664
Antipsychotic drug level increased	53.93	25.17	21	5580	3437	31688306
Intentional overdose	53.59	25.17	50	5551	41339	31650404
Aggression	52.08	25.17	47	5554	37244	31654499
Delirium	51.64	25.17	49	5552	41372	31650371
Enuresis	51.58	25.17	18	5583	2166	31689577
Tardive dyskinesia	47.42	25.17	22	5579	5537	31686206
Mental impairment	38.85	25.17	23	5578	9509	31682234
Cardiac dysfunction	37.97	25.17	14	5587	1973	31689770
Anxiety	37.93	25.17	62	5539	90971	31600772
Sexual relationship change	37.79	25.17	6	5595	17	31691726
Sopor	37.23	25.17	24	5577	11528	31680215
Completed suicide	36.34	25.17	61	5540	91453	31600290
Toxicity to various agents	36.29	25.17	91	5510	181396	31510347
Obesity	33.18	25.17	22	5579	11078	31680665
Hanging	33.17	25.17	7	5594	121	31691622
Orgasmic sensation decreased	30.79	25.17	6	5595	68	31691675
Obsessive thoughts	30.47	25.17	9	5592	634	31691109
Cyclothymic disorder	29.62	25.17	6	5595	84	31691659
Coma scale abnormal	29.48	25.17	14	5587	3709	31688034
Antipsychotic drug level above therapeutic	28.95	25.17	10	5591	1167	31690576
Respiratory fatigue	28.70	25.17	6	5595	99	31691644
Premature ejaculation	27.56	25.17	6	5595	121	31691622
Intentional self-injury	27.35	25.17	21	5580	13294	31678449
Neonatal behavioural syndrome	27.15	25.17	6	5595	130	31691613
Motor developmental delay	25.95	25.17	8	5593	652	31691091
Akathisia	25.69	25.17	16	5585	7237	31684506
Distributive shock	25.68	25.17	9	5592	1096	31690647
Labelled drug-drug interaction medication error	25.39	25.17	20	5581	13143	31678600

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug interaction	339.06	18.83	337	9672	381104	70537331
Serotonin syndrome	244.22	18.83	119	9890	41995	70876440
Myoglobin urine present	163.20	18.83	34	9975	699	70917736
Suicide attempt	162.06	18.83	114	9895	79396	70839039
Intentional overdose	153.21	18.83	120	9889	98315	70820120
Intentional self-injury	132.86	18.83	72	9937	31578	70886857
Neuroleptic malignant syndrome	114.29	18.83	61	9948	25946	70892489
Toxicity to various agents	102.87	18.83	189	9820	381983	70536452
Suicidal ideation	95.77	18.83	79	9930	69517	70848918
Loss of libido	94.90	18.83	28	9981	2469	70915966
Blood creatine phosphokinase increased	93.74	18.83	74	9935	61189	70857246
Schizophrenia	84.15	18.83	43	9966	16725	70901710
Troponin increased	81.62	18.83	42	9967	16572	70901863
Sedation	79.23	18.83	60	9949	46671	70871764
Catatonia	79.04	18.83	33	9976	8100	70910335
Drug level increased	78.20	18.83	54	9955	36415	70882020
Obsessive-compulsive disorder	77.49	18.83	29	9980	5341	70913094
Overdose	77.45	18.83	107	9902	169638	70748797
Apathy	76.06	18.83	36	9973	11872	70906563
Toxic encephalopathy	74.36	18.83	34	9975	10372	70908063
Psychotic disorder	74.27	18.83	53	9956	37648	70880787
Amylase increased	71.83	18.83	33	9976	10175	70908260
Encephalitis toxic	67.60	18.83	14	9995	279	70918156
Somnolence	67.36	18.83	114	9895	215492	70702943
Anxiety	65.55	18.83	114	9895	220216	70698219
Completed suicide	63.04	18.83	114	9895	227021	70691414
Salivary hypersecretion	61.54	18.83	32	9977	12893	70905542
Drug abuse	58.58	18.83	87	9922	147169	70771266
Sopor	52.66	18.83	40	9969	31227	70887208
Aggression	52.47	18.83	48	9961	48398	70870037
Blood potassium increased	50.58	18.83	37	9972	27289	70891146
Enuresis	50.43	18.83	18	9991	2899	70915536
Blood lactate dehydrogenase increased	46.46	18.83	39	9970	35088	70883347
Tremor	45.55	18.83	80	9929	155544	70762891
Galactorrhoea	40.71	18.83	16	9993	3362	70915073
Agitation	39.76	18.83	57	9952	93318	70825117
Oscillopsia	37.58	18.83	8	10001	183	70918252
Tardive dyskinesia	37.27	18.83	21	9988	9908	70908527
Orthostatic hypotension	37.10	18.83	41	9968	51702	70866733
Obsessive thoughts	36.61	18.83	11	9998	1032	70917403
Antipsychotic drug level increased	36.44	18.83	17	9992	5423	70913012
Hanging	35.73	18.83	7	10002	104	70918331
Akathisia	35.64	18.83	22	9987	12271	70906164
Mydriasis	34.80	18.83	24	9985	16129	70902306
Mental impairment	33.37	18.83	24	9985	17231	70901204
Sexual relationship change	32.93	18.83	5	10004	13	70918422
Depression	31.98	18.83	80	9929	198894	70719541
Cyclothymic disorder	31.19	18.83	7	10002	206	70918229
Dyspnoea	30.99	18.83	38	9971	770022	70148413
Cardiac dysfunction	29.89	18.83	13	9996	3524	70914911
Pain	29.80	18.83	27	9982	628789	70289646
Delirium	29.51	18.83	44	9965	74570	70843865
Extrapyramidal disorder	29.44	18.83	24	9985	20726	70897709
Rhabdomyolysis	27.70	18.83	49	9960	95711	70822724
Orgasmic sensation decreased	27.63	18.83	5	10004	47	70918388
Electrocardiogram QT prolonged	27.13	18.83	45	9964	83472	70834963
Labelled drug-drug interaction medication error	26.30	18.83	24	9985	24103	70894332
Semen volume decreased	26.29	18.83	5	10004	63	70918372
Gaze palsy	26.23	18.83	11	9998	2727	70915708
Antipsychotic drug level above therapeutic	26.07	18.83	10	9999	1969	70916466
Premature ejaculation	26.01	18.83	5	10004	67	70918368
Obsessive-compulsive symptom	25.90	18.83	6	10003	204	70918231
Arthralgia	25.82	18.83	20	9989	503370	70415065
Rheumatoid arthritis	25.70	18.83	5	10004	291800	70626635
Irritability	25.20	18.83	29	9980	38196	70880239
Distributive shock	24.88	18.83	10	9999	2227	70916208
Respiratory fatigue	24.62	18.83	6	10003	254	70918181
Activation syndrome	24.22	18.83	6	10003	272	70918163
Inappropriate antidiuretic hormone secretion	23.14	18.83	22	9987	23254	70895181
Restlessness	22.93	18.83	29	9980	42099	70876336
Myoclonus	22.64	18.83	23	9986	26332	70892103
Mania	22.56	18.83	19	9990	17155	70901280
Coma scale abnormal	22.20	18.83	14	9995	8102	70910333
Alice in wonderland syndrome	21.53	18.83	4	10005	44	70918391
Psychomotor skills impaired	21.52	18.83	11	9998	4273	70914162
Genital hypoaesthesia	21.47	18.83	5	10004	174	70918261
Acanthosis nigricans	21.28	18.83	5	10004	181	70918254
Brain injury	21.06	18.83	15	9994	10602	70907833
Drug screen false positive	20.25	18.83	7	10002	1026	70917409
Parkinsonism	20.23	18.83	17	9992	15308	70903127
Depressed level of consciousness	19.43	18.83	40	9969	87391	70831044
Bradycardia	18.85	18.83	49	9960	124566	70793869
Anaemia folate deficiency	18.84	18.83	5	10004	299	70918136

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06AB08	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Selective serotonin reuptake inhibitors
FDA MoA	N0000000109	Serotonin Uptake Inhibitors
CHEBI has role	CHEBI:35469	antidepressants
CHEBI has role	CHEBI:35474	anti-anxiety agents
CHEBI has role	CHEBI:50949	SSRI
FDA EPC	N0000175696	Serotonin Reuptake Inhibitor
MeSH PA	D014151	Anti-Anxiety Agents
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D018687	Antidepressive Agents, Second-Generation
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D065609	Cytochrome P-450 CYP1A2 Inhibitors
MeSH PA	D065689	Cytochrome P-450 CYP2C19 Inhibitors
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D018490	Serotonin Agents
MeSH PA	D017367	Serotonin Uptake Inhibitors
MeSH PA	D014149	Tranquilizing Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Social phobia	indication	25501002	DOID:11257
Obsessive-compulsive disorder	indication	191736004	DOID:10933
Depressive disorder	off-label use	35489007
Posttraumatic stress disorder	off-label use	47505003	DOID:2055
Bipolar affective disorder, current episode depression	off-label use	191627008	DOID:3312
Suicidal thoughts	contraindication	6471006
Bipolar disorder	contraindication	13746004	DOID:3312
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Upper gastrointestinal hemorrhage	contraindication	37372002
Syndrome of inappropriate vasopressin secretion	contraindication	55004003	DOID:3401
Blood coagulation disorder	contraindication	64779008	DOID:1247
Epilepsy	contraindication	84757009	DOID:1826
Hyponatremia	contraindication	89627008
Mania	contraindication	231494001
Hypomania	contraindication	231496004
Disease of liver	contraindication	235856003	DOID:409
Serotonin syndrome	contraindication	371089000
Breastfeeding (mother)	contraindication	413712001
Poor metabolizer due to cytochrome p450 CYP2D6 variant	contraindication	423629005
Smokes tobacco daily	contraindication	449868002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.36	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	INHIBITOR	Ki	8.51	WOMBAT-PK	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.95	PDSP
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	8.84	CHEMBL
Cytochrome P450 1A2	Enzyme	P05177	CP1A2_HUMAN		Ki	5.07	WOMBAT-PK
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	7.44	CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_RAT	INHIBITOR	Ki	8.19	IUPHAR
Sigma non-opioid intracellular receptor 1	Membrane receptor		SGMR1_RAT		Ki	7.44	CHEMBL
Sigma intracellular receptor 2	Unclassified		SGMR2_RAT		Ki	5.07	CHEMBL

External reference:

ID	Source
4023976	VUID
N0000021981	NUI
D00824	KEGG_DRUG
61718-82-9	SECONDARY_CAS_RN
4020892	VANDF
4023976	VANDF
C0085228	UMLSCUI
CHEBI:5138	CHEBI
FVX	PDB_CHEM_ID
CHEMBL814	ChEMBL_ID
DB00176	DRUGBANK_ID
CHEMBL1409	ChEMBL_ID
D016666	MESH_DESCRIPTOR_UI
5324346	PUBCHEM_CID
7189	IUPHAR_LIGAND_ID
3879	INN_ID
O4L1XPO44W	UNII
203143	RXNORM
40916	MMSL
4758	MMSL
d03804	MMSL
003633	NDDF
003634	NDDF
116522003	SNOMEDCT_US
372905008	SNOMEDCT_US
96213009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0228-2848	CAPSULE, EXTENDED RELEASE	100 mg	ORAL	ANDA	21 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0228-2849	CAPSULE, EXTENDED RELEASE	150 mg	ORAL	ANDA	21 sections
Fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1670	TABLET, FILM COATED	25 mg	ORAL	ANDA	34 sections
Fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1671	TABLET, FILM COATED	50 mg	ORAL	ANDA	34 sections
Fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1672	TABLET, FILM COATED	100 mg	ORAL	ANDA	34 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	10370-175	CAPSULE, EXTENDED RELEASE	100 mg	ORAL	ANDA	30 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	10370-175	CAPSULE, EXTENDED RELEASE	100 mg	ORAL	ANDA	30 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	10370-176	CAPSULE, EXTENDED RELEASE	150 mg	ORAL	ANDA	30 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	10370-176	CAPSULE, EXTENDED RELEASE	150 mg	ORAL	ANDA	30 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	16590-270	TABLET	25 mg	ORAL	NDA	11 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	33261-683	TABLET, COATED	50 mg	ORAL	NDA AUTHORIZED GENERIC	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5988	TABLET, COATED	100 mg	ORAL	NDA authorized generic	31 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	60505-0164	TABLET	25 mg	ORAL	ANDA	32 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	60505-0165	TABLET	50 mg	ORAL	ANDA	32 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	60505-0166	TABLET	100 mg	ORAL	ANDA	32 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	62559-158	TABLET, COATED	25 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	62559-159	TABLET, COATED	50 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	62559-160	TABLET, COATED	100 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8018	TABLET, COATED	25 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	68071-2337	TABLET, COATED	50 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	68151-0637	TABLET, COATED	50 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	68788-7219	TABLET, COATED	100 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	68788-7219	TABLET, COATED	100 mg	ORAL	NDA authorized generic	31 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	68788-8175	TABLET	100 mg	ORAL	ANDA	32 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	69452-182	CAPSULE, EXTENDED RELEASE	100 mg	ORAL	ANDA	22 sections
Fluvoxamine Maleate	HUMAN PRESCRIPTION DRUG LABEL	1	69452-183	CAPSULE, EXTENDED RELEASE	150 mg	ORAL	ANDA	22 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	70518-1057	TABLET, COATED	100 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	70518-1057	TABLET, COATED	100 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	70518-1643	TABLET, COATED	50 mg	ORAL	NDA authorized generic	31 sections
fluvoxamine maleate	HUMAN PRESCRIPTION DRUG LABEL	1	70518-1789	TABLET, COATED	25 mg	ORAL	NDA authorized generic	31 sections